PTPRC and plasma cell myeloma: Changes observed in TRAIL receptor levels were mainly myeloma specific since expression of TRAIL receptors in CD138-/CD45+compartment of bone marrow did not get affected by bortezomib treatment irrespective of del(8)(p21) status (S1 Fig).